Dallas, Texas / New Taipei City, Taiwan | November 11, 2026
Nutraceuticals Corporation Inc. and Taiwan-based Rosetta Pharmamate Co., Ltd. have entered into a Mutual Confidentiality Agreement (CDA), effective November 6, 2026, to facilitate discussions regarding potential pharmaceutical and biotechnology collaboration.
The agreement establishes a framework for the confidential exchange of scientific, technical, financial, business, and regulatory information. It enables both companies to evaluate potential commercial opportunities while protecting proprietary technologies, formulations, intellectual property, and other sensitive materials.
Exploring Potential Areas of Cooperation
The agreement creates an opportunity for Nutraceuticals and Rosetta to explore areas of mutual interest within the pharmaceutical industry, including potential product development, manufacturing, technology cooperation, licensing, and commercial arrangements.
Any future collaboration will remain subject to additional discussions, due diligence, regulatory considerations, and separate definitive agreements.
The execution of the confidentiality agreement represents an initial step in evaluating potential opportunities and does not constitute a finalized commercial partnership, manufacturing appointment, licensing agreement, investment commitment, or regulatory approval.
About Nutraceuticals Corporation
Nutraceuticals Corporation is a US-based pharmaceutical and biotechnology development company focused on advancing scientific, regulatory, and commercial development opportunities.
About Rosetta Pharmamate Co., Ltd.
Rosetta Pharmamate Co., Ltd. is a Taiwan-based pharmaceutical company exploring potential business opportunities with Nutraceuticals Corporation through the confidential evaluation framework established by the agreement.
Forward-Looking Statements
This announcement contains forward-looking statements concerning potential business opportunities and future commercial discussions. These statements are subject to risks and uncertainties. Neither party guarantees that discussions will result in a definitive commercial transaction or partnership.